by admin | Oct 21, 2019 | Licensing
ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates. Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to...
by admin | Oct 21, 2019 | Funding
AI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises US$56m in a Series B financing and launches global accelerator programme for orphan diseases. The financing was led by Atomico and joined by Intel Capital, Global Brain and btov Partners as new...
by admin | Oct 21, 2019 | Funding
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion. The financing round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation as well as existing private investors....
by admin | Oct 8, 2019 | Clinical Trials
The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease. In a 200-patient phase III trial that finished in July, Jazz...
by admin | Oct 8, 2019 | M&A - Buy-Out
US medical device company AngioDynamics Inc. (NASDAQ: ANGO) announced an agreement to acquire Israel laser technology developer Eximo Medical Ltd. for $46 million and up to $20 million in milestone payments. Based in Rehovot, Eximo Medical is an early commercial...
